Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of a monthly administration of
Fulvestrant in patients with recurrent or metastatic endometrial carcinoma by assessment of
the clinical tumour response after 3 injections.